Dashboard
Manage Tickers

HURA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
TuHURA Biosciences Q2 EPS $(0.21) Misses $...
08/14/2025 20:42:57

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

Core News & Articles
Florida Rep. Laurel Lee Sold Up to $265K W...
08/12/2025 15:00:33

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
08/11/2025 17:06:46

Core News & Articles
TuHURA Biosciences Added To Russell 3000 I...
07/01/2025 12:51:17

Core News & Articles
TuHURA Biosciences Initiates Phase 3 Accel...
06/24/2025 12:01:47

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
06/23/2025 21:06:48

Core News & Articles
TuHURA Biosciences And Kineta Receive Stoc...
06/23/2025 21:04:08

Core News & Articles
FDA Removes Manufacturing-Related Partial ...
06/09/2025 12:11:11

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembro...

Core News & Articles
TuHURA Biosciences Presents IFx-Hu2.0 Tria...
06/02/2025 12:14:33

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients wi...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on TuHU...
05/16/2025 11:12:08

HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $12 price ...

Core News & Articles
TuHURA Biosciences Q1 EPS $(0.15) Misses $...
05/15/2025 20:37:12

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of ...

Core News & Articles
TuHURA Biosciences Initiates Phase 1b/2a S...
05/05/2025 12:05:33

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered ...

Core News & Articles
TuHURA Biosciences And Kineta Present Upda...
04/28/2025 12:09:23

Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg

Core News & Articles
HC Wainwright & Co. Maintains Buy on TuHUR...
04/03/2025 11:47:40

HC Wainwright & Co. analyst Robert Burns maintains TuHURA Biosciences (NASDAQ:HURA) with a Buy and lowers the price targ...

Core News & Articles
TuHURA Biosciences FY24 EPS ($1.21) Up Fro...
04/01/2025 12:13:56

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
03/19/2025 17:06:05

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
03/18/2025 17:05:46

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
03/13/2025 12:09:33

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
03/12/2025 21:08:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION